|
TOP NEWS
Takeda Liable In IBS Drug Pay-For-Delay Trial
By Carolyn Muyskens
A federal jury in Boston on Monday found Takeda Pharmaceuticals conspired with a generic-drug maker to delay the launch of a generic version of Takeda's anti-constipation drug, awarding purchasers $885 million, a figure that's expected to swell after a rule tripling plaintiffs' antitrust damages is applied.
Read full article »
| Save to favorites »
U.S. SUPREME COURT
LITIGATION
Aetna Denied A Freeze On Trans Facial Surgery Order
By Kellie Mejdrich
A Connecticut federal judge ordered Aetna to comply with a preliminary injunction requiring it to reconsider coverage denials affecting two transgender health plan participants who sought gender-affirming facial surgery, refusing to stay the insurer's compliance obligations during its pending appeal in the proposed class action.
Order attached |
Read full article »
| Save to favorites »
Health Co. Wants Kirkland Off IP Case For 'Cardinal Sin'
By Elliot Weld
A healthcare company suing medical technology company Commure Inc. over alleged trade secret theft has said Kirkland & Ellis LLP should be disqualified from representing Commure because the healthcare company had tried to retain Kirkland prior to filing the suit and shared confidential information before anyone asked who the defendant was going to be.
Motion attached |
Read full article »
| Save to favorites »
EXPERT ANALYSIS
'Skinny Label' Arguments Spotlight Induced Infringement Risk
Recent oral arguments before the U.S. Supreme Court in Hikma Pharmaceuticals v. Amarin Pharma highlight the uncertain boundary between lawful generic competition through so-called skinny labels and induced patent infringement, with potential implications for patent holders’ communication, enforcement and causation strategies across industries, says Anton Hopen at Trenam.
Transcript attached |
Read full article »
| Save to favorites »
LEGAL INDUSTRY
Ex-Willkie Atty Banned By SEC For Insider Trading
By Emily Sawicki
A former Willkie Farr & Gallagher LLP mergers and acquisitions attorney who earlier this month admitted to taking part in a widespread BigLaw insider trading scheme will be barred from representing a client before the U.S. Securities and Exchange Commission for a minimum of four years, according to an order the agency issued Monday.
Order attached |
Read full article »
| Save to favorites »
|